Nonpersistent Nanoarchitectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head/Neck Carcinoma
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(28)
Published: May 18, 2024
Cisplatin
chemoradiotherapy
(CRT)
is
the
established
standard
of
care
for
managing
locally
advanced
human
papillomavirus-positive
head/neck
carcinoma.
The
typically
young
patients
may
suffer
serious
and
long-time
side
effects
caused
by
treatment,
such
as
dysphagia,
hearing
loss.
Thus,
ensuring
a
satisfactory
post-treatment
quality
life
paramount.
One
potential
replacing
approach
to
classical
CRT
involves
combination
standard-dose
radiotherapy
radiosensitizers
noble
metal
nanoparticles
(NPs).
However,
several
concerns
about
size,
shape,
biocompatibility
limit
translation
nanomaterials
clinical
practice.
Here,
it
demonstrated
that
new
model
nonpersistent
gold
nanoarchitectures
containing
cisplatin
(NAs-Cluster-CisPt)
generates,
in
with
radiotherapy,
significant
vivo
tumor-reducing
effect
compared
CRT,
achieving
complete
tumor
clearance
25%
immunocompetent
models
persist
60
days.
These
findings,
together
negligible
amount
metals
recognized
excretory
organs,
highlight
concurrent
administration
NAs-Cluster-CisPt
has
overcome
some
limitations
associated
NP-based
approaches
while
enhancing
treatment
outcome
respect
CRT.
Overall,
despite
further
mechanistic
investigations
being
essential,
these
data
support
exploiting
metal-nanomaterial-mediated
oral
cancer
management.
Language: Английский
In Vivo Combined Photoacoustic Imaging and Photothermal Treatment of HPV‐Negative Head and Neck Carcinoma with NIR‐Responsive Non‐Persistent Plasmon Nano‐Architectures
Advanced Therapeutics,
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 6, 2024
Abstract
The
combination
of
photoacoustic
imaging
(PAI)
and
photothermal
therapy
(PTT)
is
an
attractive
approach
in
cancer
management
due
to
the
non‐invasive
features
combined
with
real‐time
selective
tissue
damage
by
non‐ionizing
radiation.
This
especially
appealing
for
Head
Neck
Squamous
Cell
Carcinoma
(HNSCC)
management,
where
up
40%
patients
require
modifications
treatment
regimen.
On
other
hand,
most
agents
developed
PAI/PTT
suffer
from
persistence
or
re‐shaping
issues.
Here,
a
unique
non‐persistent
plasmon
nano‐architecture
(
t
NAs‐IRDye)
presented
that
simultaneously
acts
as
contrast
agent
PAI
transducer
PTT.
NAs‐IRDye
are
fully
characterized
evaluated
vitro
ex
vivo,
their
performance
theranostic
assessed
HPV‐negative
HNSCC
murine
models.
A
significant
modulation
tumor
growth
obtained
vivo
upon
intratumoral
injection
subsequent
NIR
irradiation
compared
solely
irradiated
control.
outcomes
this
study
exhibit
noteworthy
potential
foster
development
innovative
clinical
strategies
head
neck
carcinoma.
Language: Английский
Neoadjuvant Hyperthermia Combined with Hybrid Nanoarchitectures Enhances Chemoradiotherapy Efficacy in Head and Neck Carcinoma
ACS Applied Materials & Interfaces,
Journal Year:
2024,
Volume and Issue:
16(33), P. 43272 - 43282
Published: Aug. 10, 2024
Head
and
neck
squamous
cell
carcinomas
are
characterized
by
a
high
incidence
of
recurrence,
especially
in
patients
with
locally
advanced
disease.
Standard
treatment
strategies
can
be
associated
severe
side
effects
to
healthy
tissues
that
negatively
impact
the
patient's
quality
life.
Hyperthermia
(HT)
is
noninvasive
modality
has
improved
effectiveness
chemotherapy
(CT)
and/or
radiotherapy
(RT)
for
management
some
solid
neoplasms.
In
this
context,
association
approach
rationally
designed
nanomaterials
may
further
enhance
outcome.
study,
we
demonstrate
enhanced
effect
neoadjuvant
HT
combination
hybrid
nanoarchitectures
enclosing
cisplatin
prodrug
(NAs-CisPt)
RT.
All
treatments
their
combinations
have
been
fully
evaluated
employing
standardized
chorioallantoic
membrane
tumor
models
HPV-negative
head
carcinoma.
An
tumor-shrinking
was
observed
administration
trimodal
(HT/NAs-CisPt/RT),
which
also
highlighted
significant
increase
apoptosis.
Our
findings
nanotechnology-based
CT
RT
certain
order
enhances
vivo
On
broader
basis,
study
paves
way
next
exploration
approaches
clinical
oral
cancer
based
on
innovative
strategies.
Language: Английский
Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: April 21, 2024
Oral
malignancies
continue
to
have
severe
morbidity
with
less
than
50%
long-term
survival
despite
the
advancement
in
available
therapies.
There
is
a
persisting
demand
for
new
approaches
establish
more
efficient
strategies
their
treatment.
In
this
regard,
human
topoisomerase
II
(topoII)
enzyme
validated
chemotherapeutics
target,
as
topoII
regulates
vital
cellular
processes
such
DNA
replication,
transcription,
recombination,
and
chromosome
segregation
cells.
TopoII
inhibitors
are
currently
used
treat
some
neoplasms
breast
small
cells
lung
carcinomas.
Additionally,
under
investigation
treatment
of
other
cancer
types,
including
oral
cancer.
Here,
we
report
therapeutic
effect
tetrahydroquinazoline
derivative
(named
ARN21934)
that
preferentially
inhibits
alpha
isoform
topoII.
The
efficacy
ARN21934
has
been
evaluated
2D
cell
cultures,
3D
vitro
systems,
chick
chorioallantoic
membrane
models.
Overall,
work
paves
way
further
preclinical
developments
possibly
promising
chemical
class
chemotherapeutic
approach
neoplasms.
Language: Английский